Different Symptoms Important to Kidney Cancer Patients and Clinicians

Published Jun 17, 2013
Chicago, IL, USA - The patient’s perspective is fast becoming an important component for health care decisions. For example, the Food and Drug Administration now has guidance for the development of patient-reported outcome instruments. Patients with advanced kidney cancer are most concerned about fatigue, treatment side effects, and worry about one’s condition getting worse. Kidney cancer physicians more readily focus on symptoms that suggest disease progression or factors that can reduce or delay treatment such as bone pain, fever, and weight loss. The NFKSI-19 symptom index demonstrated preliminary reliability and validity supporting its use in assessing health-related quality of life in clinical trials and routine clinical practice. Health-related quality of life is critical, particularly when curative treatment options are limited. Both the clinician and patient perspectives have been included in the article “Development and Initial Validation of the NCCN/FACT Symptom Index for Advanced Kidney Cancer,” published in Value in Health. Nan Rothrock, PhD, author of the study states, “By utilizing both patient and clinician perspectives, we have a measure that addresses patients’ concerns about quality of life as well as symptoms that are critical for treatment planning.”

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

New Research Reveals Surprising Trends in Women's Health Economics Authorship

May 12, 2025

Value in Health, the official journal of ISPOR announced the publication of new research analyzing women's representation in authorship of papers submitted to and published in Value in Health. The report, “How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

Redefining Value in Care for Alzheimer's Disease and Dementia

Apr 8, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that provide crucial insights into the complex health economics of Alzheimer's disease and related dementias (ADRD), offering a roadmap for future research and policy as the aging population grows and novel treatments emerge.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×